Golden, CO– PharmaJet has announced a new partnership with Immuno Cure to advance clinical development of a needle-free, therapeutic DNA vaccine for HIV. The agreement was formalized during the 2025 BIO International Convention in Boston and will support upcoming human trials using PharmaJet’s Tropis® intradermal (ID) delivery system.
The vaccine, known as ICVAX, targets HIV-1 and aims to offer a functional cure by enabling virological control without antiretroviral therapy. Building on successful early-phase clinical trials that demonstrated strong safety and immunogenicity, the new study will explore whether needle-free ID administration can enhance immune response and patient experience.
“Our mission is to advance transformative therapies for infectious diseases and cancer,” said Dr. Xia Jin, CEO of Immuno Cure. “Partnering with PharmaJet allows us to explore innovative delivery methods that could improve both the effectiveness of the vaccine and comfort for patients.”
PharmaJet’s Tropis system delivers vaccines intradermally, taking advantage of the dense network of dendritic cells and T cells in the dermal layer to potentially generate stronger and broader immune responses than traditional intramuscular injections. The system is the first and only WHO-prequalified needle-free ID technology and has been used in over 12 million injections globally.
“This agreement adds to our growing portfolio of partnerships focused on challenging outdated intramuscular delivery methods,” said Dan Mallon, Senior Vice President of Corporate Development at PharmaJet. “We believe needle-free ID delivery represents the future of immunization—offering better efficacy, safety, and patient experience.”
The collaboration reflects increasing momentum around novel vaccine platforms and delivery technologies in the fight against HIV and other infectious diseases.
